GIOVANNELLI, Simona
 Distribuzione geografica
Continente #
NA - Nord America 3.320
EU - Europa 2.642
AS - Asia 1.320
SA - Sud America 221
AF - Africa 34
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 2
Totale 7.567
Nazione #
US - Stati Uniti d'America 3.229
IT - Italia 1.387
SG - Singapore 438
GB - Regno Unito 318
CN - Cina 302
IE - Irlanda 258
SE - Svezia 161
BR - Brasile 153
VN - Vietnam 146
HK - Hong Kong 143
DE - Germania 122
RU - Federazione Russa 74
UA - Ucraina 71
BD - Bangladesh 69
FR - Francia 64
FI - Finlandia 53
IN - India 44
NL - Olanda 44
CA - Canada 40
TR - Turchia 34
BG - Bulgaria 24
KR - Corea 24
AR - Argentina 23
ID - Indonesia 21
MX - Messico 20
IQ - Iraq 15
LT - Lituania 13
CO - Colombia 11
MY - Malesia 9
PL - Polonia 9
VE - Venezuela 9
EG - Egitto 8
ES - Italia 8
IR - Iran 8
ZA - Sudafrica 8
EC - Ecuador 7
JP - Giappone 7
PK - Pakistan 7
SA - Arabia Saudita 7
AL - Albania 6
CL - Cile 6
CR - Costa Rica 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
CH - Svizzera 5
UZ - Uzbekistan 5
IL - Israele 4
JO - Giordania 4
KE - Kenya 4
PR - Porto Rico 4
PT - Portogallo 4
PY - Paraguay 4
SV - El Salvador 4
TW - Taiwan 4
UY - Uruguay 4
AT - Austria 3
AZ - Azerbaigian 3
BE - Belgio 3
CZ - Repubblica Ceca 3
MA - Marocco 3
SC - Seychelles 3
TH - Thailandia 3
TT - Trinidad e Tobago 3
AM - Armenia 2
AU - Australia 2
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
LB - Libano 2
NG - Nigeria 2
NI - Nicaragua 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
EU - Europa 1
GF - Guiana Francese 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
ME - Montenegro 1
MZ - Mozambico 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
QA - Qatar 1
TJ - Tagikistan 1
Totale 7.540
Città #
Ashburn 468
Singapore 288
Santa Clara 286
Dublin 256
Chandler 201
Southend 193
San Jose 191
Fairfield 184
Woodbridge 142
Hong Kong 139
Dearborn 134
Milan 122
Council Bluffs 120
Jacksonville 114
Rome 100
Beijing 98
Nyköping 98
Houston 85
New York 85
Ann Arbor 84
Seattle 71
Wilmington 66
Cambridge 62
London 52
Los Angeles 46
Ho Chi Minh City 43
Bologna 36
Naples 36
Helsinki 35
Hanoi 34
Bari 32
Munich 29
The Dalles 29
Hefei 25
Palermo 25
Florence 24
Columbus 22
Izmir 22
Princeton 22
Turin 22
Eugene 21
Modena 21
San Diego 21
Sofia 21
São Paulo 21
Lauterbourg 19
Seoul 18
Genoa 17
Dong Ket 16
Jakarta 15
Phoenix 15
Shanghai 15
Moscow 14
Brooklyn 12
Chicago 12
Denver 12
Orem 12
Verona 12
Catania 11
Vicenza 11
Buffalo 10
Dallas 10
Pisa 10
Toronto 10
Boardman 9
Bremen 9
Guangzhou 9
Padova 9
Springfield 9
Atlanta 8
Brescia 8
Chennai 8
Ferrara 8
Perugia 8
Redondo Beach 8
Venice 8
York 8
Fremont 7
Haiphong 7
Montreal 7
San Mateo 7
Trieste 7
Ancona 6
Cagliari 6
Miami 6
Monte Porzio 6
Norwalk 6
Philadelphia 6
Porto Alegre 6
Reading 6
Redwood City 6
Reggio Emilia 6
Turku 6
Caracas 5
Des Moines 5
Frankfurt am Main 5
Hải Dương 5
Lecce 5
Saint Augustine 5
San José 5
Totale 4.722
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.191
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 515
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 449
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 414
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 411
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 409
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 399
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 367
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 347
Biomarker expression and survival after primary chemotherapy for breast cancer. 333
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 333
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 295
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 262
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’ 255
Operable Breast Cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/- gefitinib with biomarkers evaluation 254
IMPROVED SURVIVAL AFTER RADIOTHERAPY FOR BRAIN METASTASES IN PATIENTS WITH HER2 POSITIVE BREAST TUMORS 250
Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives 237
LAPATINIB IN ASSOCIAZIONE A CAPECITABINA IN PAZIENTI CON CARCINOMA MAMMARIO METASTTICO HER2 POSITIVO IN PROGRESSIONE DOPO TERAPIA CON TRASTUZUMAB 229
CARCINOMI MAMMARI HER2 POSITIVI: CASISTICA DI MODENA 217
CHEMOTHERAPY-INDUCED MODULATION OF BIOMARKERS EXPRESSION IN PRIMARY BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 208
VALUTAZIONE DEL RISCHIO DI TOSSICITA’ CARDIACA DI TRASTUZUMAB IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO IN TRATTAMENTO ADIUVANTE 192
Totale 7.567
Categoria #
all - tutte 22.089
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.089


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022258 0 0 0 0 7 23 20 9 50 16 88 45
2022/2023866 81 76 29 64 52 67 13 48 310 30 59 37
2023/2024766 36 45 44 48 82 68 53 111 38 69 88 84
2024/20251.328 57 65 45 129 220 193 80 96 171 66 74 132
2025/20261.997 128 67 123 228 340 132 243 97 181 237 127 94
2026/2027643 54 119 187 255 28 0 0 0 0 0 0 0
Totale 7.567